Therapy preference and decision-making among patients with severe sickle cell anemia and their families

Jane Hankins, Pamela Hinds, Sara Day, Yvonne Carroll, Chin-Shang Li, Patricia Garvie, Winfred Wang

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Background. Patients with severe sickle cell anemia (SCA) may benefit from therapeutic intervention with hydroxyurea (HU), chronic red cell transfusion (CT), or stem cell transplantation (SCT). Determination of best treatment is complicated by the tradeoff between each treatment's risks and benefits and the lack of data comparing them to determine efficacy. We explored factors that influenced making decisions regarding interventions and examined the relations between treatment preference and health-related quality of life (HRQOL). Methods. Children with severe SCA and their parents received brochures describing each treatment, discussed risk/benefits with a nurse-educator, and answered questions regarding HRQOL and the factors influencing treatment preference. Severe SCA was defined as ≥3 pain events requiring ER visits or hospitalizations within 12 months, ≥2 acute chest syndrome (ACS) events within 24 months, or a combination of the two. Results. Thirty parents and 7 patients participated. HU was preferred by 21 parents and 4 children, CT by 5 parents and 1 child, and SCT by 3 parents and 1 child. One parent was undecided and one child preferred no treatment. Interviewees were most influenced by perceived efficacy and safety, but no factors differed significantly among treatment preference groups. HRQOL median scores (0-100 scale) for parents (56; range, 28-91) and children (61; range, 31-96) did not differ significantly among treatment preference groups. Conclusions. Patients with severe SCA and their parents can identify their treatment preferences. Improved understanding of their preferences and decision-making process will aid in the design of future clinical trials and in medical decision-making.

Original languageEnglish (US)
Pages (from-to)705-710
Number of pages6
JournalPediatric Blood and Cancer
Volume48
Issue number7
DOIs
StatePublished - Jun 15 2007
Externally publishedYes

Fingerprint

Sickle Cell Anemia
Decision Making
Parents
Therapeutics
Hydroxyurea
Quality of Life
Stem Cell Transplantation
Acute Chest Syndrome
Pamphlets
Hospitalization
Nurses
Clinical Trials
Safety
Pain

Keywords

  • Decision-making
  • Quality of life
  • Sickle cell anemia
  • Sickle cell disease

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Therapy preference and decision-making among patients with severe sickle cell anemia and their families. / Hankins, Jane; Hinds, Pamela; Day, Sara; Carroll, Yvonne; Li, Chin-Shang; Garvie, Patricia; Wang, Winfred.

In: Pediatric Blood and Cancer, Vol. 48, No. 7, 15.06.2007, p. 705-710.

Research output: Contribution to journalArticle

Hankins, Jane ; Hinds, Pamela ; Day, Sara ; Carroll, Yvonne ; Li, Chin-Shang ; Garvie, Patricia ; Wang, Winfred. / Therapy preference and decision-making among patients with severe sickle cell anemia and their families. In: Pediatric Blood and Cancer. 2007 ; Vol. 48, No. 7. pp. 705-710.
@article{56f9eb60da33466d8cae243ce34092af,
title = "Therapy preference and decision-making among patients with severe sickle cell anemia and their families",
abstract = "Background. Patients with severe sickle cell anemia (SCA) may benefit from therapeutic intervention with hydroxyurea (HU), chronic red cell transfusion (CT), or stem cell transplantation (SCT). Determination of best treatment is complicated by the tradeoff between each treatment's risks and benefits and the lack of data comparing them to determine efficacy. We explored factors that influenced making decisions regarding interventions and examined the relations between treatment preference and health-related quality of life (HRQOL). Methods. Children with severe SCA and their parents received brochures describing each treatment, discussed risk/benefits with a nurse-educator, and answered questions regarding HRQOL and the factors influencing treatment preference. Severe SCA was defined as ≥3 pain events requiring ER visits or hospitalizations within 12 months, ≥2 acute chest syndrome (ACS) events within 24 months, or a combination of the two. Results. Thirty parents and 7 patients participated. HU was preferred by 21 parents and 4 children, CT by 5 parents and 1 child, and SCT by 3 parents and 1 child. One parent was undecided and one child preferred no treatment. Interviewees were most influenced by perceived efficacy and safety, but no factors differed significantly among treatment preference groups. HRQOL median scores (0-100 scale) for parents (56; range, 28-91) and children (61; range, 31-96) did not differ significantly among treatment preference groups. Conclusions. Patients with severe SCA and their parents can identify their treatment preferences. Improved understanding of their preferences and decision-making process will aid in the design of future clinical trials and in medical decision-making.",
keywords = "Decision-making, Quality of life, Sickle cell anemia, Sickle cell disease",
author = "Jane Hankins and Pamela Hinds and Sara Day and Yvonne Carroll and Chin-Shang Li and Patricia Garvie and Winfred Wang",
year = "2007",
month = "6",
day = "15",
doi = "10.1002/pbc.20903",
language = "English (US)",
volume = "48",
pages = "705--710",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Therapy preference and decision-making among patients with severe sickle cell anemia and their families

AU - Hankins, Jane

AU - Hinds, Pamela

AU - Day, Sara

AU - Carroll, Yvonne

AU - Li, Chin-Shang

AU - Garvie, Patricia

AU - Wang, Winfred

PY - 2007/6/15

Y1 - 2007/6/15

N2 - Background. Patients with severe sickle cell anemia (SCA) may benefit from therapeutic intervention with hydroxyurea (HU), chronic red cell transfusion (CT), or stem cell transplantation (SCT). Determination of best treatment is complicated by the tradeoff between each treatment's risks and benefits and the lack of data comparing them to determine efficacy. We explored factors that influenced making decisions regarding interventions and examined the relations between treatment preference and health-related quality of life (HRQOL). Methods. Children with severe SCA and their parents received brochures describing each treatment, discussed risk/benefits with a nurse-educator, and answered questions regarding HRQOL and the factors influencing treatment preference. Severe SCA was defined as ≥3 pain events requiring ER visits or hospitalizations within 12 months, ≥2 acute chest syndrome (ACS) events within 24 months, or a combination of the two. Results. Thirty parents and 7 patients participated. HU was preferred by 21 parents and 4 children, CT by 5 parents and 1 child, and SCT by 3 parents and 1 child. One parent was undecided and one child preferred no treatment. Interviewees were most influenced by perceived efficacy and safety, but no factors differed significantly among treatment preference groups. HRQOL median scores (0-100 scale) for parents (56; range, 28-91) and children (61; range, 31-96) did not differ significantly among treatment preference groups. Conclusions. Patients with severe SCA and their parents can identify their treatment preferences. Improved understanding of their preferences and decision-making process will aid in the design of future clinical trials and in medical decision-making.

AB - Background. Patients with severe sickle cell anemia (SCA) may benefit from therapeutic intervention with hydroxyurea (HU), chronic red cell transfusion (CT), or stem cell transplantation (SCT). Determination of best treatment is complicated by the tradeoff between each treatment's risks and benefits and the lack of data comparing them to determine efficacy. We explored factors that influenced making decisions regarding interventions and examined the relations between treatment preference and health-related quality of life (HRQOL). Methods. Children with severe SCA and their parents received brochures describing each treatment, discussed risk/benefits with a nurse-educator, and answered questions regarding HRQOL and the factors influencing treatment preference. Severe SCA was defined as ≥3 pain events requiring ER visits or hospitalizations within 12 months, ≥2 acute chest syndrome (ACS) events within 24 months, or a combination of the two. Results. Thirty parents and 7 patients participated. HU was preferred by 21 parents and 4 children, CT by 5 parents and 1 child, and SCT by 3 parents and 1 child. One parent was undecided and one child preferred no treatment. Interviewees were most influenced by perceived efficacy and safety, but no factors differed significantly among treatment preference groups. HRQOL median scores (0-100 scale) for parents (56; range, 28-91) and children (61; range, 31-96) did not differ significantly among treatment preference groups. Conclusions. Patients with severe SCA and their parents can identify their treatment preferences. Improved understanding of their preferences and decision-making process will aid in the design of future clinical trials and in medical decision-making.

KW - Decision-making

KW - Quality of life

KW - Sickle cell anemia

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=34248198838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248198838&partnerID=8YFLogxK

U2 - 10.1002/pbc.20903

DO - 10.1002/pbc.20903

M3 - Article

VL - 48

SP - 705

EP - 710

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -